The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Type 2 Inflammation Targeting Drugs Market Research Report 2025

Global Type 2 Inflammation Targeting Drugs Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1932248

No of Pages : 101

Ask Your Query
Synopsis
Anaphylaxis is an inappropriate reaction of the immune system to normal harmless substances. It generally has a rapid onset, strong reaction, and rapid subsidence. It has obvious genetic tendencies and individual differences. Currently, the prevalence of allergic diseases is increasing rapidly worldwide, affecting approximately 25% of the global population.
Abnormalities in type 2 immune pathways are important factors in inducing allergic diseases. Type 2 immune pathway refers to an inflammatory pathway in which Th2 cells (T helper 2) play a key role, and various cytokines such as IL-4, IL-5, IL-13, and TSLP are involved.
Depending on where the inflammatory reaction occurs, abnormal type 2 immune pathways can induce different allergic diseases, such as skin (atopic dermatitis, chronic spontaneous urticaria, etc.), respiratory tract (chronic sinusitis, asthma, chronic obstruction, etc.) lung disease, etc.), digestive tract (eosinophilic esophagitis), cardiovascular (eosinophilic granulomatous vasculitis), etc.
Biological targeted drugs mainly reduce the inflammatory response and activity of immune cells by binding to targets such as specific regulatory factors in the type 2 immune pathway; Small molecule targeted drugs include JAK inhibitors and TYK2 inhibitors, which exert immunomodulatory effects by blocking the JAK/STAT pathway. Compared with traditional anti-allergic drugs, targeted drugs have better efficacy in severe or drug-resistant patients, and the drugs themselves are safer, and have gradually become the mainstream trend in the development of anti-allergic drugs.
The global Type 2 Inflammation Targeting Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Type 2 Inflammation Targeting Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Type 2 Inflammation Targeting Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Type 2 Inflammation Targeting Drugs in Atopic Dermatitis is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Type 2 Inflammation Targeting Drugs include Sanofi, Novartis, GSK, Amgen, AstraZeneca, Pfizer, Teva, Otsuka Pharmaceutical and Roche, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Type 2 Inflammation Targeting Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Type 2 Inflammation Targeting Drugs.
Report Scope
The Type 2 Inflammation Targeting Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Type 2 Inflammation Targeting Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Type 2 Inflammation Targeting Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi
Novartis
GSK
Amgen
AstraZeneca
Pfizer
Teva
Otsuka Pharmaceutical
Roche
AbbVie
Leo Pharma
Eli Lilly and Company
Keymed Biosciences
Mabpharm
Genrix Bio
Dragon Boat Pharmaceutical
Jiangsu Hengrui Pharmaceuticals
Sunshine Guojian
Qyuns Therapeutics
Biosion
Segment by Type
IL-4R
TSLP
IL-5
JAK
IgE
IL-13
IL-33
Others
Segment by Application
Atopic Dermatitis
Asthma
Chronic Sinusitis with Nasal Polyps
Chronic Obstructive Pulmonary Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Type 2 Inflammation Targeting Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IL-4R
1.2.3 TSLP
1.2.4 IL-5
1.2.5 JAK
1.2.6 IgE
1.2.7 IL-13
1.2.8 IL-33
1.2.9 Others
1.3 Market by Application
1.3.1 Global Type 2 Inflammation Targeting Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Atopic Dermatitis
1.3.3 Asthma
1.3.4 Chronic Sinusitis with Nasal Polyps
1.3.5 Chronic Obstructive Pulmonary Disease
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Type 2 Inflammation Targeting Drugs Market Perspective (2019-2030)
2.2 Type 2 Inflammation Targeting Drugs Growth Trends by Region
2.2.1 Global Type 2 Inflammation Targeting Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Type 2 Inflammation Targeting Drugs Historic Market Size by Region (2019-2024)
2.2.3 Type 2 Inflammation Targeting Drugs Forecasted Market Size by Region (2025-2030)
2.3 Type 2 Inflammation Targeting Drugs Market Dynamics
2.3.1 Type 2 Inflammation Targeting Drugs Industry Trends
2.3.2 Type 2 Inflammation Targeting Drugs Market Drivers
2.3.3 Type 2 Inflammation Targeting Drugs Market Challenges
2.3.4 Type 2 Inflammation Targeting Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Type 2 Inflammation Targeting Drugs Players by Revenue
3.1.1 Global Top Type 2 Inflammation Targeting Drugs Players by Revenue (2019-2024)
3.1.2 Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Type 2 Inflammation Targeting Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Type 2 Inflammation Targeting Drugs Revenue
3.4 Global Type 2 Inflammation Targeting Drugs Market Concentration Ratio
3.4.1 Global Type 2 Inflammation Targeting Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Type 2 Inflammation Targeting Drugs Revenue in 2023
3.5 Type 2 Inflammation Targeting Drugs Key Players Head office and Area Served
3.6 Key Players Type 2 Inflammation Targeting Drugs Product Solution and Service
3.7 Date of Enter into Type 2 Inflammation Targeting Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Type 2 Inflammation Targeting Drugs Breakdown Data by Type
4.1 Global Type 2 Inflammation Targeting Drugs Historic Market Size by Type (2019-2024)
4.2 Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Type (2025-2030)
5 Type 2 Inflammation Targeting Drugs Breakdown Data by Application
5.1 Global Type 2 Inflammation Targeting Drugs Historic Market Size by Application (2019-2024)
5.2 Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Type 2 Inflammation Targeting Drugs Market Size (2019-2030)
6.2 North America Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024)
6.4 North America Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Type 2 Inflammation Targeting Drugs Market Size (2019-2030)
7.2 Europe Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024)
7.4 Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size (2019-2030)
8.2 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Type 2 Inflammation Targeting Drugs Market Size (2019-2030)
9.2 Latin America Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024)
9.4 Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size (2019-2030)
10.2 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Type 2 Inflammation Targeting Drugs Introduction
11.1.4 Sanofi Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Type 2 Inflammation Targeting Drugs Introduction
11.2.4 Novartis Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Type 2 Inflammation Targeting Drugs Introduction
11.3.4 GSK Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.3.5 GSK Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Type 2 Inflammation Targeting Drugs Introduction
11.4.4 Amgen Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.4.5 Amgen Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Type 2 Inflammation Targeting Drugs Introduction
11.5.4 AstraZeneca Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Type 2 Inflammation Targeting Drugs Introduction
11.6.4 Pfizer Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Teva
11.7.1 Teva Company Detail
11.7.2 Teva Business Overview
11.7.3 Teva Type 2 Inflammation Targeting Drugs Introduction
11.7.4 Teva Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.7.5 Teva Recent Development
11.8 Otsuka Pharmaceutical
11.8.1 Otsuka Pharmaceutical Company Detail
11.8.2 Otsuka Pharmaceutical Business Overview
11.8.3 Otsuka Pharmaceutical Type 2 Inflammation Targeting Drugs Introduction
11.8.4 Otsuka Pharmaceutical Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.8.5 Otsuka Pharmaceutical Recent Development
11.9 Roche
11.9.1 Roche Company Detail
11.9.2 Roche Business Overview
11.9.3 Roche Type 2 Inflammation Targeting Drugs Introduction
11.9.4 Roche Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.9.5 Roche Recent Development
11.10 AbbVie
11.10.1 AbbVie Company Detail
11.10.2 AbbVie Business Overview
11.10.3 AbbVie Type 2 Inflammation Targeting Drugs Introduction
11.10.4 AbbVie Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.10.5 AbbVie Recent Development
11.11 Leo Pharma
11.11.1 Leo Pharma Company Detail
11.11.2 Leo Pharma Business Overview
11.11.3 Leo Pharma Type 2 Inflammation Targeting Drugs Introduction
11.11.4 Leo Pharma Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.11.5 Leo Pharma Recent Development
11.12 Eli Lilly and Company
11.12.1 Eli Lilly and Company Company Detail
11.12.2 Eli Lilly and Company Business Overview
11.12.3 Eli Lilly and Company Type 2 Inflammation Targeting Drugs Introduction
11.12.4 Eli Lilly and Company Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.12.5 Eli Lilly and Company Recent Development
11.13 Keymed Biosciences
11.13.1 Keymed Biosciences Company Detail
11.13.2 Keymed Biosciences Business Overview
11.13.3 Keymed Biosciences Type 2 Inflammation Targeting Drugs Introduction
11.13.4 Keymed Biosciences Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.13.5 Keymed Biosciences Recent Development
11.14 Mabpharm
11.14.1 Mabpharm Company Detail
11.14.2 Mabpharm Business Overview
11.14.3 Mabpharm Type 2 Inflammation Targeting Drugs Introduction
11.14.4 Mabpharm Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.14.5 Mabpharm Recent Development
11.15 Genrix Bio
11.15.1 Genrix Bio Company Detail
11.15.2 Genrix Bio Business Overview
11.15.3 Genrix Bio Type 2 Inflammation Targeting Drugs Introduction
11.15.4 Genrix Bio Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.15.5 Genrix Bio Recent Development
11.16 Dragon Boat Pharmaceutical
11.16.1 Dragon Boat Pharmaceutical Company Detail
11.16.2 Dragon Boat Pharmaceutical Business Overview
11.16.3 Dragon Boat Pharmaceutical Type 2 Inflammation Targeting Drugs Introduction
11.16.4 Dragon Boat Pharmaceutical Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.16.5 Dragon Boat Pharmaceutical Recent Development
11.17 Jiangsu Hengrui Pharmaceuticals
11.17.1 Jiangsu Hengrui Pharmaceuticals Company Detail
11.17.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.17.3 Jiangsu Hengrui Pharmaceuticals Type 2 Inflammation Targeting Drugs Introduction
11.17.4 Jiangsu Hengrui Pharmaceuticals Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.17.5 Jiangsu Hengrui Pharmaceuticals Recent Development
11.18 Sunshine Guojian
11.18.1 Sunshine Guojian Company Detail
11.18.2 Sunshine Guojian Business Overview
11.18.3 Sunshine Guojian Type 2 Inflammation Targeting Drugs Introduction
11.18.4 Sunshine Guojian Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.18.5 Sunshine Guojian Recent Development
11.19 Qyuns Therapeutics
11.19.1 Qyuns Therapeutics Company Detail
11.19.2 Qyuns Therapeutics Business Overview
11.19.3 Qyuns Therapeutics Type 2 Inflammation Targeting Drugs Introduction
11.19.4 Qyuns Therapeutics Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.19.5 Qyuns Therapeutics Recent Development
11.20 Biosion
11.20.1 Biosion Company Detail
11.20.2 Biosion Business Overview
11.20.3 Biosion Type 2 Inflammation Targeting Drugs Introduction
11.20.4 Biosion Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024)
11.20.5 Biosion Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of IL-4R
Table 3. Key Players of TSLP
Table 4. Key Players of IL-5
Table 5. Key Players of JAK
Table 6. Key Players of IgE
Table 7. Key Players of IL-13
Table 8. Key Players of IL-33
Table 9. Key Players of Others
Table 10. Global Type 2 Inflammation Targeting Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 11. Global Type 2 Inflammation Targeting Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global Type 2 Inflammation Targeting Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 13. Global Type 2 Inflammation Targeting Drugs Market Share by Region (2019-2024)
Table 14. Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 15. Global Type 2 Inflammation Targeting Drugs Market Share by Region (2025-2030)
Table 16. Type 2 Inflammation Targeting Drugs Market Trends
Table 17. Type 2 Inflammation Targeting Drugs Market Drivers
Table 18. Type 2 Inflammation Targeting Drugs Market Challenges
Table 19. Type 2 Inflammation Targeting Drugs Market Restraints
Table 20. Global Type 2 Inflammation Targeting Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 21. Global Type 2 Inflammation Targeting Drugs Market Share by Players (2019-2024)
Table 22. Global Top Type 2 Inflammation Targeting Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Type 2 Inflammation Targeting Drugs as of 2023)
Table 23. Ranking of Global Top Type 2 Inflammation Targeting Drugs Companies by Revenue (US$ Million) in 2023
Table 24. Global 5 Largest Players Market Share by Type 2 Inflammation Targeting Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Type 2 Inflammation Targeting Drugs Product Solution and Service
Table 27. Date of Enter into Type 2 Inflammation Targeting Drugs Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Type 2 Inflammation Targeting Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 30. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Type (2019-2024)
Table 31. Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 32. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Type (2025-2030)
Table 33. Global Type 2 Inflammation Targeting Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 34. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Application (2019-2024)
Table 35. Global Type 2 Inflammation Targeting Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 36. Global Type 2 Inflammation Targeting Drugs Revenue Market Share by Application (2025-2030)
Table 37. North America Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. North America Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 39. North America Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 40. Europe Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 42. Europe Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 43. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 44. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 45. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 46. Latin America Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 48. Latin America Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 49. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 50. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 51. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 52. Sanofi Company Detail
Table 53. Sanofi Business Overview
Table 54. Sanofi Type 2 Inflammation Targeting Drugs Product
Table 55. Sanofi Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 56. Sanofi Recent Development
Table 57. Novartis Company Detail
Table 58. Novartis Business Overview
Table 59. Novartis Type 2 Inflammation Targeting Drugs Product
Table 60. Novartis Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 61. Novartis Recent Development
Table 62. GSK Company Detail
Table 63. GSK Business Overview
Table 64. GSK Type 2 Inflammation Targeting Drugs Product
Table 65. GSK Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 66. GSK Recent Development
Table 67. Amgen Company Detail
Table 68. Amgen Business Overview
Table 69. Amgen Type 2 Inflammation Targeting Drugs Product
Table 70. Amgen Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 71. Amgen Recent Development
Table 72. AstraZeneca Company Detail
Table 73. AstraZeneca Business Overview
Table 74. AstraZeneca Type 2 Inflammation Targeting Drugs Product
Table 75. AstraZeneca Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 76. AstraZeneca Recent Development
Table 77. Pfizer Company Detail
Table 78. Pfizer Business Overview
Table 79. Pfizer Type 2 Inflammation Targeting Drugs Product
Table 80. Pfizer Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 81. Pfizer Recent Development
Table 82. Teva Company Detail
Table 83. Teva Business Overview
Table 84. Teva Type 2 Inflammation Targeting Drugs Product
Table 85. Teva Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 86. Teva Recent Development
Table 87. Otsuka Pharmaceutical Company Detail
Table 88. Otsuka Pharmaceutical Business Overview
Table 89. Otsuka Pharmaceutical Type 2 Inflammation Targeting Drugs Product
Table 90. Otsuka Pharmaceutical Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 91. Otsuka Pharmaceutical Recent Development
Table 92. Roche Company Detail
Table 93. Roche Business Overview
Table 94. Roche Type 2 Inflammation Targeting Drugs Product
Table 95. Roche Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 96. Roche Recent Development
Table 97. AbbVie Company Detail
Table 98. AbbVie Business Overview
Table 99. AbbVie Type 2 Inflammation Targeting Drugs Product
Table 100. AbbVie Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 101. AbbVie Recent Development
Table 102. Leo Pharma Company Detail
Table 103. Leo Pharma Business Overview
Table 104. Leo Pharma Type 2 Inflammation Targeting Drugs Product
Table 105. Leo Pharma Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 106. Leo Pharma Recent Development
Table 107. Eli Lilly and Company Company Detail
Table 108. Eli Lilly and Company Business Overview
Table 109. Eli Lilly and Company Type 2 Inflammation Targeting Drugs Product
Table 110. Eli Lilly and Company Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 111. Eli Lilly and Company Recent Development
Table 112. Keymed Biosciences Company Detail
Table 113. Keymed Biosciences Business Overview
Table 114. Keymed Biosciences Type 2 Inflammation Targeting Drugs Product
Table 115. Keymed Biosciences Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 116. Keymed Biosciences Recent Development
Table 117. Mabpharm Company Detail
Table 118. Mabpharm Business Overview
Table 119. Mabpharm Type 2 Inflammation Targeting Drugs Product
Table 120. Mabpharm Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 121. Mabpharm Recent Development
Table 122. Genrix Bio Company Detail
Table 123. Genrix Bio Business Overview
Table 124. Genrix Bio Type 2 Inflammation Targeting Drugs Product
Table 125. Genrix Bio Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 126. Genrix Bio Recent Development
Table 127. Dragon Boat Pharmaceutical Company Detail
Table 128. Dragon Boat Pharmaceutical Business Overview
Table 129. Dragon Boat Pharmaceutical Type 2 Inflammation Targeting Drugs Product
Table 130. Dragon Boat Pharmaceutical Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 131. Dragon Boat Pharmaceutical Recent Development
Table 132. Jiangsu Hengrui Pharmaceuticals Company Detail
Table 133. Jiangsu Hengrui Pharmaceuticals Business Overview
Table 134. Jiangsu Hengrui Pharmaceuticals Type 2 Inflammation Targeting Drugs Product
Table 135. Jiangsu Hengrui Pharmaceuticals Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 136. Jiangsu Hengrui Pharmaceuticals Recent Development
Table 137. Sunshine Guojian Company Detail
Table 138. Sunshine Guojian Business Overview
Table 139. Sunshine Guojian Type 2 Inflammation Targeting Drugs Product
Table 140. Sunshine Guojian Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 141. Sunshine Guojian Recent Development
Table 142. Qyuns Therapeutics Company Detail
Table 143. Qyuns Therapeutics Business Overview
Table 144. Qyuns Therapeutics Type 2 Inflammation Targeting Drugs Product
Table 145. Qyuns Therapeutics Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 146. Qyuns Therapeutics Recent Development
Table 147. Biosion Company Detail
Table 148. Biosion Business Overview
Table 149. Biosion Type 2 Inflammation Targeting Drugs Product
Table 150. Biosion Revenue in Type 2 Inflammation Targeting Drugs Business (2019-2024) & (US$ Million)
Table 151. Biosion Recent Development
Table 152. Research Programs/Design for This Report
Table 153. Key Data Information from Secondary Sources
Table 154. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Type 2 Inflammation Targeting Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Type 2 Inflammation Targeting Drugs Market Share by Type: 2023 VS 2030
Figure 3. IL-4R Features
Figure 4. TSLP Features
Figure 5. IL-5 Features
Figure 6. JAK Features
Figure 7. IgE Features
Figure 8. IL-13 Features
Figure 9. IL-33 Features
Figure 10. Others Features
Figure 11. Global Type 2 Inflammation Targeting Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 12. Global Type 2 Inflammation Targeting Drugs Market Share by Application: 2023 VS 2030
Figure 13. Atopic Dermatitis Case Studies
Figure 14. Asthma Case Studies
Figure 15. Chronic Sinusitis with Nasal Polyps Case Studies
Figure 16. Chronic Obstructive Pulmonary Disease Case Studies
Figure 17. Others Case Studies
Figure 18. Type 2 Inflammation Targeting Drugs Report Years Considered
Figure 19. Global Type 2 Inflammation Targeting Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 20. Global Type 2 Inflammation Targeting Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 21. Global Type 2 Inflammation Targeting Drugs Market Share by Region: 2023 VS 2030
Figure 22. Global Type 2 Inflammation Targeting Drugs Market Share by Players in 2023
Figure 23. Global Top Type 2 Inflammation Targeting Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Type 2 Inflammation Targeting Drugs as of 2023)
Figure 24. The Top 10 and 5 Players Market Share by Type 2 Inflammation Targeting Drugs Revenue in 2023
Figure 25. North America Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. North America Type 2 Inflammation Targeting Drugs Market Share by Country (2019-2030)
Figure 27. United States Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Canada Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Type 2 Inflammation Targeting Drugs Market Share by Country (2019-2030)
Figure 31. Germany Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. France Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. U.K. Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Italy Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Russia Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Nordic Countries Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Type 2 Inflammation Targeting Drugs Market Share by Region (2019-2030)
Figure 39. China Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Japan Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. South Korea Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Southeast Asia Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. India Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Australia Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Latin America Type 2 Inflammation Targeting Drugs Market Share by Country (2019-2030)
Figure 47. Mexico Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Brazil Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Type 2 Inflammation Targeting Drugs Market Share by Country (2019-2030)
Figure 51. Turkey Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Saudi Arabia Type 2 Inflammation Targeting Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Sanofi Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 54. Novartis Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 55. GSK Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 56. Amgen Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 57. AstraZeneca Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 58. Pfizer Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 59. Teva Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 60. Otsuka Pharmaceutical Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 61. Roche Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 62. AbbVie Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 63. Leo Pharma Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 64. Eli Lilly and Company Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 65. Keymed Biosciences Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 66. Mabpharm Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 67. Genrix Bio Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 68. Dragon Boat Pharmaceutical Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 69. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 70. Sunshine Guojian Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 71. Qyuns Therapeutics Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 72. Biosion Revenue Growth Rate in Type 2 Inflammation Targeting Drugs Business (2019-2024)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock